Jefferies Financial Group reaffirmed their buy rating on shares of CareDx (NASDAQ:CDNA) in a research note issued to investors on Monday, AnalystRatings.com reports. Jefferies Financial Group currently has a $35.00 price target on the stock.

A number of other equities analysts have also issued reports on CDNA. Raymond James raised their price target on shares of CareDx from $40.00 to $42.00 and gave the stock a strong-buy rating in a research report on Wednesday, August 5th. HC Wainwright raised their price target on shares of CareDx from $37.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday, August 5th. BTIG Research raised their price target on shares of CareDx from $40.00 to $45.00 and gave the stock a buy rating in a research report on Thursday, August 6th. Zacks Investment Research lowered shares of CareDx from a hold rating to a sell rating in a research report on Tuesday, June 23rd. Finally, Piper Sandler reissued a buy rating and set a $54.00 price target on shares of CareDx in a research report on Monday, June 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $43.38.

CDNA stock opened at $31.33 on Monday. The firm has a 50 day moving average of $33.74 and a 200 day moving average of $27.66. The stock has a market capitalization of $1.53 billion, a PE ratio of -71.20 and a beta of 1.01. The company has a quick ratio of 4.26, a current ratio of 4.42 and a debt-to-equity ratio of 0.07. CareDx has a 52 week low of $13.04 and a 52 week high of $37.54.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, August 4th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $41.80 million during the quarter, compared to analysts’ expectations of $35.61 million. CareDx had a negative net margin of 12.66% and a negative return on equity of 13.58%. CareDx’s revenue for the quarter was up 32.9% compared to the same quarter last year. On average, equities research analysts expect that CareDx will post -0.75 earnings per share for the current year.

In other news, CEO Peter Maag sold 13,008 shares of CareDx stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $36.77, for a total transaction of $478,304.16. Following the completion of the transaction, the chief executive officer now directly owns 425,134 shares of the company’s stock, valued at approximately $15,632,177.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sasha King sold 25,402 shares of CareDx stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $33.10, for a total transaction of $840,806.20. Following the transaction, the insider now directly owns 28,334 shares of the company’s stock, valued at $937,855.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 148,410 shares of company stock valued at $4,958,683. Insiders own 3.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CDNA. Rockefeller Capital Management L.P. purchased a new stake in CareDx in the 2nd quarter worth $36,000. Steward Partners Investment Advisory LLC increased its holdings in CareDx by 754.7% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 1,735 shares of the company’s stock worth $37,000 after acquiring an additional 1,532 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in CareDx by 267.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,836 shares of the company’s stock worth $41,000 after acquiring an additional 1,336 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in CareDx in the 2nd quarter worth $47,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in CareDx by 58.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,817 shares of the company’s stock worth $61,000 after acquiring an additional 1,038 shares in the last quarter.

About CareDx

CareDx, Inc, a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients.

See Also: How can you know how many shares are floating?

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.